Pharmaceutical composition for prevention of diet induced obesity
Inventors
SINGH, Ankit Shyam • MISHRA, Vedprakash • TONGRA, Neelima
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10702487-B2
Publication Date
2020-07-07
Expiration Date
Abstract
The present invention relates to a pharmaceutical composition/formulation for the prevention of diet induced obesity. More particularly, the invention relates to a composition/formulation comprising a synergistic combination of Oleoylethanolamide (OEA) and other natural ingredients can be used for treatment of obesity and its related disorders associated with fat metabolism like non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD). This can also be helpful in controlling obesity by way of maintaining body weight. The invention also provides various formulations and methods of preparing the same.
Core Innovation
The invention relates to a pharmaceutical composition for preventing diet-induced obesity and for treating obesity-related fat metabolism disorders. The composition centers on a synergistic combination comprising oleoylethanolamide (OEA), naturally occurring β-aminoisobutyric acid (BAIBA), and a natural antioxidant.
The core composition requires specific weight ranges for OEA, naturally occurring BAIBA, and a natural antioxidant. The composition is stated to provide a synergistic effect compared to OEA alone, BAIBA alone, or the natural antioxidant alone.
The document also describes optional additional components in the composition, including a natural α-glucosidase inhibitor and/or a natural FAAH inhibitor. The invention further includes example oral dosage forms and formulation concepts for administering the composition.
Claims Coverage
The independent claim covers a pharmaceutical composition defined by three constrained ingredients: OEA, naturally occurring BAIBA/BAIBA-associated amino acid selection, and a selected natural antioxidant, with a required synergistic effect versus each individual ingredient. The inventive features are constrained by weight ranges and specified selection lists, with dependent claims further refining specific ingredient choices, optional inhibitor additions, and supported oral dosage forms and excipients.
Synergistic combination of OEA, naturally occurring BAIBA, and natural antioxidant
A pharmaceutical composition comprising oleoylethanolamide (OEA) ranging from 10 to 70% by wt. of the composition; naturally occurring β-aminoisobutyric acid (BAIBA) ranging from 2 to 60% by wt. of the composition and selected from the group consisting of valine, iso-leucine and combinations thereof; and natural anti-oxidant ranging from 20 to 35% by wt. of the composition and selected from the group consisting of vitamin E, glutathione, pantethine, fucoxanthin and combinations thereof, wherein the pharmaceutical composition provides a synergistic effect as compared to the OEA alone, the naturally occurring BAIBA alone, or the natural anti-oxidant alone.
Overall, the claim coverage centers on a three-component composition with specified weight-percentage ranges for OEA, naturally occurring BAIBA, and a selected natural antioxidant, where the composition is stated to produce a synergistic effect versus each component alone.
Stated Advantages
Provides a synergistic effect as compared to the OEA alone, the naturally occurring BAIBA alone, or the natural anti-oxidant alone.
Documented Applications
Preventing diet-induced obesity.
Treating obesity-related fat metabolism disorders, including NAFLD/NASH and progression to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
Interested in licensing this patent?